Teladoc Health Announces Chief Financial Officer Transition

(NYSE:TDOC), NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) — Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced that Mala Murthy will be stepping down from her role as Chief Financial Officer to pursue an opportunity outside of the healthcare industry. Ms. Murthy will continue to serve in her role until her […]

Treace to Report Third Quarter 2025 Financial Results on November 6, 2025

(NASDAQ:TMCI), PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2025 after the close of

Baker Hughes Declares Quarterly Dividend

(NASDAQ:BKR), HOUSTON and LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR) announced today that the Baker Hughes Board of Directors declared a quarterly cash dividend of $0.23 per share of Class A common stock payable on Nov. 14, 2025, to holders of record on Nov. 4, 2025. Baker Hughes expects to fund

Nature’s Sunshine Sets Third Quarter 2025 Conference Call for Thursday, November 6, 2025, at 5:00 p.m. ET

(NASDAQ:NATR), LEHI, Utah, Oct. 23, 2025 (GLOBE NEWSWIRE) — Nature's Sunshine Products, Inc. (Nasdaq: NATR) (“Nature's Sunshine”) (the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, November 6, 2025, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the third

Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025

(NASDAQ:CDTX), SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak(R) platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its third quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, November 6,

Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025

(NASDAQ:SGHT), MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the third quarter ended September 30, 2025,

CPS Announces $384.6 Million Senior Subordinate Asset-Backed Securitization

CPS Announces $384.6 Million Senior Subordinate Asset-Backed Securitization GlobeNewswire October 23, 2025 LAS VEGAS, Nevada, Oct. 23, 2025 (GLOBE NEWSWIRE) — Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) announced the closing of its fourth term securitization in 2025 on Thursday October 23, 2025. The transaction is CPS's 57th senior subordinate securitization since

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors GlobeNewswire October 23, 2025 SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the

USBC Partners with Uphold and Vast Bank to Launch the First Retail Tokenized Deposits, Designed to Provide Worldwide Access to U.S. Dollar Deposit Accounts

USBC Partners with Uphold and Vast Bank to Launch the First Retail Tokenized Deposits, Designed to Provide Worldwide Access to U.S. Dollar Deposit Accounts Combines traditional banking protections with blockchain innovation, bringing real U.S. dollar deposits securely on-chain with global accessibility GlobeNewswire October 23, 2025 RENO, Nev., Oct. 23, 2025 (GLOBE NEWSWIRE) — USBC, Inc.

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire October 23, 2025 Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple KRASG12D and KRASG12V cell-derived xenograft

Scroll to Top